roche__tree

Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma

pharmafile | November 25, 2019 | News story | Research and Development, Sales and Marketing |ย ย Cancer, Roche, immunotherapy, pharma, tecentriqย 

Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the treatment of unresectable hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy.

The company announced the findings at the European Society for Medical Oncology (ESMO) Asia Congress 2019 on Saturday.

The data illustrated that Rocheโ€™s combo boosted overall survival rates by 42% and progression-free survival rates by 41% compared to Bayerโ€™s Nexavar (sorafenib) โ€“ improvements which Roche called โ€œsignificant and clinically meaningfulโ€.

โ€œFor the first time in a decade, we are seeing a treatment that has improved overall survival for people with unresectable hepatocellular carcinoma compared with the current standard of care,โ€ said Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development. โ€œTecentriq in combination with Avastin could transform the treatment of this aggressive disease, and we are working closely with global health authorities in the hope of bringing this treatment option to patients as soon as possible.โ€

Advertisement

Tecentriq is currently undergoing Phase 3 trials in a range of indications with further studies planning, including in lung, skin, breast, head and neck, gastrointestinal, gynaecological and genitourinary cancers.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

CuraCell granted approval for trial of new therapy for metastatic cancers

Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a …

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

The Gateway to Local Adoption Series

Latest content